MUMBAI, India, June 26 -- Intellectual Property India has published a patent application (202617013858 A) filed by Araris Biotech AG on February 09, 2026, for Antibody-Drug Conjugates Using Two Different Types Of Topoisomerase I Inhibitors.
Inventors include Bertrand, Romain; Attinger-Toller, Isabella; Probst, Philipp; Fay, Rachael; Kallenberger, Lia; Grabulovski, Dragan; and Spycher, Philipp.
The application for the patent was published on June 19, 2026, under issue no. 25/2026.
Abstract: Described is an antibody-drug conjugate (ADC) having the formula A-L, wherein A is an antibody or an antibody fragment and wherein L is a linker, said linker comprising: as a first payload a topoisomerase I inhibitor which is cell-permeable, preferably a camptothecin cytotoxic molecule which is cell-permeable; and as a second payload a topoisomerase I inhibitor which is not cell-permeable, preferably a camptothecin cytotoxic molecule which is not cell-permeable. Moreover, described is a pharmaceutical composition comprising said ADC and at least one pharmaceutically acceptable ingredient. Further, described is an ADC for use in a method of treating a patient suffering from, being at risk of developing, and/or being diagnosed for a neoplastic disease.
Disclaimer: Curated by HT Syndication.
